This therapeutic approach targets cholinergic basal forebrain dysfunction and visual processing circuit impairment in Dementia with Lewy Bodies (DLB), addressing the core neuropsychiatric symptoms that distinguish DLB from other dementias.
| Dimension | Score | Rationale |
|---|---|---|
| Novelty | 8 | Novel combination of basal forebrain + visual circuit targeting |
| Mechanistic Rationale | 9 | Direct targeting of DLB-specific cholinergic and visual pathway dysfunction |
| Root-Cause Coverage | 7 | Addresses symptomatic pathways; α-synuclein pathology remains |
| Delivery Feasibility | 7 | Existing AChEI delivery routes (oral); novel delivery can use intranasal |
| Safety Plausibility | 8 | AChEI safety established |
| Combinability | 8 | Can combine with current AChEIs, pimavanserin |
| Biomarker Availability | 7 | Cholinergic PET imaging (CHAT), sleep studies for RBD |
| De-risking Path | 7 | Clear regulatory path via AChEI precedent |
| Multi-disease Potential | 6 | DLB primary; applicable to PDD |
| Patient Impact | 9 | High unmet need - visual hallucinations cause major disability |
Total Score: 76/100
| Disease | Coverage | Rationale |
|---|---|---|
| Dementia with Lewy Bodies | 10 | Primary indication; addresses core symptoms |
| Parkinson's Disease Dementia | 8 | Similar cholinergic dysfunction |
| Parkinson's Disease | 5 | RBD and some cholinergic involvement |
| Alzheimer's Disease | 3 | Some cholinergic loss but different pattern |